2.29Open2.29Pre Close0 Volume115 Open Interest5.00Strike Price0.00Turnover152.17%IV22.79%PremiumJan 17, 2025Expiry Date1.49Intrinsic Value100Multiplier13DDays to Expiry0.80Extrinsic Value100Contract SizeAmericanOptions Type-0.8574Delta0.2239Gamma2.26Leverage Ratio-0.0081Theta-0.0013Rho-1.94Eff Leverage0.0015Vega
Perspective Therapeutics Stock Discussion
I don't even trust my mind
losing everybody
they can never take my grind
📊⚡️📊
Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024
Perspective Therapeutics (NYSE AMERICAN: CATX) announced the upcoming presentation of initial results from their Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 NANETS Multidisciplinary NET Medical Symposium. The presentation, titled 'Preliminary safety and eff...
Larger Image: tradingview.com...
$Perspective Therapeutics (CATX.US)$
No comment yet